Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Endevica Bio logo — Reversing cachexia and improving quality of life in cancer p...

Endevica Bio

Reversing cachexia and improving quality of life in cancer patients. Phase 1 trial underway.

Founded 2009 United States Columbia, United States 20 employees Series B Total: $14.00M Biotechnology, Health and Wellness +1

General Information

Company Name Endevica Bio
Founded Year 2009
Location United States Columbia, United States
Employees 20
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Endevica Bio. To contact Endevica Bio, visit endevicabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Endevica Bio compare?

A PDF of Endevica Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Endevica Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Endevica Bio

Endevica Bio, founded in 2009, is making strides in the Biotechnology and Pharmaceutical industries with a focus on addressing health and wellness. The company is headquartered in the United States.

The startup's mission, encapsulated in their slogan, “Reversing cachexia and improving quality of life in cancer patients,” reflects their dedication to innovative healthcare solutions. Their lead drug candidate, a peptide therapeutic for treating cachexia related to cancer and other chronic conditions, is currently undergoing Phase 1 clinical trials in the US.

Endevica Bio recently secured a significant $10.00M Series B investment as of January 19th, 2023. This funding will likely bolster their ongoing clinical efforts and support further development activities.

The company stands out in the rapidly evolving biotech space by addressing critical unmet medical needs, presenting a compelling case for investment consideration.

Business keywords: Endevica Bio, peptide therapeutic, cancer cachexia, Phase 1 clinical trials, clinical-stage biopharmaceutical company, peptide drug candidates, drug safety, efficacy properties, technology platform, patented technology, peptide modification, half-life improvement, oral activity, blood-brain barrier, drug development

Services & Products

Development of peptide-based therapies
Conducting Phase 2 trials for oncology and metabolic disorders
Research and development in novel peptidomimetics
Providing science-driven solutions in medicine

Target Customers

Healthcare providers Oncologists Metabolic disorder specialists Pharmaceutical companies Patients affected by cancer cachexia and obesity

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $10.00M -
19 Jan 2023
Grant $2.30M 1
National Cancer Institute
01 Sep 2016
Series A $1.70M 1
Centennial Investors
Centennial Investors
01 Jun 2016

Endevica Bio Alternatives & Competitors

View All Alternatives
Endevica Bio vs
BBB Therapeutics
BBB Therapeutics The Netherlands

Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...

21 employees
Biopharma, Biotechnology
Endevica Bio vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
Endevica Bio vs
TransPharma Medical
TransPharma Medical

Pioneering transdermal drug delivery to enhance therapeutic outcomes for osteoporosis and other pept...

Series C
Biotechnology, Health Care
View all alternatives

FAQ About Endevica Bio

Reversing cachexia and improving quality of life in cancer patients. Phase 1 trial underway.
Endevica Bio was founded in 2009.
Endevica Bio is headquartered in Columbia, United States.
Endevica Bio operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Endevica Bio, peptide therapeutic, cancer cachexia and Phase 1 clinical trials. Its customers include Healthcare providers, Oncologists and Metabolic disorder specialists.
Endevica Bio has approximately 20 employees.
Endevica Bio has completed 3 funding rounds, raising a total of $14.00M. The latest funding stage is Series B.
Endevica Bio offers: Development of peptide-based therapies, Conducting Phase 2 trials for oncology and metabolic disorders, Research and development in novel peptidomimetics, Providing science-driven solutions in medicine.
Top alternatives and competitors to Endevica Bio include BBB Therapeutics, Cybrexa Therapeutics, TransPharma Medical, Agennix, Lumos Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Endevica Bio and BBB Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Endevica Bio, https://bouncewatch.com/company/endevica-bio, updated 27 October 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes